tace


Also found in: Thesaurus, Medical, Legal, Acronyms, Wikipedia.

tace

(tæs; teɪs)
n
(Arms & Armour (excluding Firearms)) a less common word for tasset

tasse

(tæs)

also tas•set

(ˈtæs ɪt)
n.
one of the plates forming the fauld in a suit of armor.
[1540–50]
Mentioned in ?
References in periodicals archive ?
Most tumors in our study were treated with TACE, which is the most common modality used in patients awaiting liver transplant.
While blocking TACE could be another way to treat rheumatoid arthritis, researchers know this strategy would likely have side effects since patients lacking TACE are prone to skin infections and intestinal lesions.
He said that globally the success of the TACE has been rated as high in critical cases and the procedure will bring a new method of treatment to liver cancer patients in the UAE.
The summer TACE event is a unique opportunity for inmates to spend quality time with their children in a nontraditional prison setting.
In spite of the improvement in performance, the TACE still suffers from the same limitations as the CAGE (i.
control arm of conventional TACE (cTACE) in hepatocellular carcinoma (HCC).
Astellas Pharma, Nippon Kayaku and Pfizer are three of the manufacturers of gelatin sponge particles, with Nippon Kayaku being the only company to offer a size calibrated product and an approved indication for use in TACE.
8 ng/ml active IDE and has minimal cross reaction with Neprilysin, TACE, b-Secretase, ADAM10 and BACE2.
The trial evaluated the safety and preliminary efficacy in lowering the incidence of tumor recurrence and metastasis by means of autologous immune cell therapy in primary HCC patients following standard tumor resection and TACE chemotherapy.
Radiofrequency ablation (RFA) and cryoablation are already considered sound treatment options, while transarterial chemoembolization (TACE) is probably the worldwide standard for treatment of unresectable hepatocellular carcinoma, with drug-eluting beads being the first major technology advancement in TACE.
PRECISION TACEacents with Drug-Eluting Beads plus placebo, or to PRECISION TACE with
This application follows the phase II survival data announced by BioAlliance Pharma in March 2011 and showing a doubled median survival in Livatag([R])treated patients (32 months, to be compared with 15 months for patients treated with best of care TACE transarterial chemoembolisation with a cytotoxic drug).